Arbutus Biopharma said it will repurchase $230 million of its common shares at a purchase price of not less than $5 per share and not more than $5.75 apiece, in cash.
Harmony Biosciences announced the appointment of Stephen Mollichella, SVP and Controller, as Interim Principal Financial Officer to ensure continuity in financial leadership while it searches for a permanent CFO.
Newsmax reported total quarterly revenues of $52.2 million for the three-month period ended December 31, 2025, representing a 9.6% year-over-year increase.
Culper Research said it has little faith in T1’s management, nor the company’s disclosures and financial reporting and said that shares are headed far lower.